Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) Director Steven D. Cosler acquired 7,000 shares of the stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $21.22 per share, with a total value of $148,540.00. Following the purchase, the director now directly owns 17,713 shares in the company, valued at $375,869.86. This represents a 65.34 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Guardian Pharmacy Services Stock Performance
NYSE:GRDN opened at $21.28 on Thursday. Guardian Pharmacy Services, Inc. has a one year low of $14.16 and a one year high of $23.05.
Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($2.00) EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($2.19). The business had revenue of $314.39 million during the quarter, compared to analysts' expectations of $303.21 million. As a group, sell-side analysts expect that Guardian Pharmacy Services, Inc. will post 0.86 EPS for the current fiscal year.
Analyst Ratings Changes
Healthcare Takes A Big Step Forward With The Help of A.I.
From Wall Street Star | Ad
To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems.
For its next act, AI is going to help save lives.
Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.
Click here to learn more about the booming eHealth industry - and see which microcap will be at the
Several brokerages have recently weighed in on GRDN. Truist Financial upped their price objective on shares of Guardian Pharmacy Services from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday, November 15th. Stephens initiated coverage on Guardian Pharmacy Services in a research note on Tuesday, October 22nd. They issued an "overweight" rating and a $21.00 price objective for the company. Finally, Raymond James initiated coverage on Guardian Pharmacy Services in a research report on Monday, October 21st. They set an "outperform" rating and a $21.00 target price on the stock.
View Our Latest Research Report on GRDN
Hedge Funds Weigh In On Guardian Pharmacy Services
A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP bought a new position in shares of Guardian Pharmacy Services in the third quarter valued at approximately $8,400,000. Allspring Global Investments Holdings LLC purchased a new position in Guardian Pharmacy Services in the third quarter worth $5,460,000. Maven Securities LTD purchased a new position in Guardian Pharmacy Services in the third quarter worth $3,033,000. Seven Grand Managers LLC bought a new position in Guardian Pharmacy Services in the 3rd quarter valued at $2,515,000. Finally, Foundry Partners LLC purchased a new stake in shares of Guardian Pharmacy Services during the 3rd quarter valued at $1,680,000.
Guardian Pharmacy Services Company Profile
(
Get Free Report)
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
